Literature DB >> 16914973

Influence of highly active antiretroviral therapy on persistence of HIV in the central nervous system.

Avindra Nath1, Ned Sacktor.   

Abstract

PURPOSE OF REVIEW: The epidemiology of HIV infection is changing rapidly in the era of highly actively antiretroviral therapy, as the use of such therapy is increasing in all countries. This has had a significant impact on the neurological manifestations of HIV infection, posing new challenges in diagnosis and treatment. This review provides a critical analysis of the recent literature on the impact of highly actively antiretroviral therapy on HIV-related neurological complications and changes in treatment strategies. RECENT
FINDINGS: It is becoming clear that the brain is an important reservoir for the virus, and neuroinflammatory and neurodegenerative changes may continue despite the adequate use of highly actively antiretroviral therapy. Although this antiretroviral therapy has had a significant impact on the severity of HIV dementia, cognitive impairment persists. With improvement in the immune status following treatment with antiretrovirals, in rare cases the brain can become a target of the immune reconstitution.
SUMMARY: Highly actively antiretroviral therapy may need to be optimized in patients with HIV-associated cognitive impairment to achieve maximal central nervous system penetration; however, this therapeutic strategy may not be sufficient for halting the process. In some instances, the antiretroviral drugs themselves may become the problem. New strategies for neuroprotection that also target host genes which control HIV replication are being developed.

Entities:  

Mesh:

Year:  2006        PMID: 16914973     DOI: 10.1097/01.wco.0000236614.51592.ca

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  47 in total

1.  Soluble and cell-associated insulin receptor dysfunction correlates with severity of HAND in HIV-infected women.

Authors:  Yamil Gerena; Richard L Skolasky; Joyce M Velez; Dianedis Toro-Nieves; Raul Mayo; Avindra Nath; Valerie Wojna
Journal:  PLoS One       Date:  2012-05-22       Impact factor: 3.240

2.  APOE epsilon4 and MBL-2 O/O genotypes are associated with neurocognitive impairment in HIV-infected plasma donors.

Authors:  Stephen A Spector; Kumud K Singh; Saurabh Gupta; Lucette A Cystique; Hua Jin; Scott Letendre; Rachel Schrier; Zunyou Wu; Kun X Hong; Xin Yu; Chuan Shi; Robert K Heaton
Journal:  AIDS       Date:  2010-06-19       Impact factor: 4.177

3.  Gene delivery of antioxidant enzymes inhibits human immunodeficiency virus type 1 gp120-induced expression of caspases.

Authors:  J-P Louboutin; L Agrawal; B A S Reyes; E J van Bockstaele; D S Strayer
Journal:  Neuroscience       Date:  2012-04-21       Impact factor: 3.590

4.  Biomarkers of HIV-1-associated neurocognitive disorders: challenges of proteomic approaches.

Authors:  Pawel Ciborowski
Journal:  Biomark Med       Date:  2009-12       Impact factor: 2.851

5.  HIV Non-Nucleoside Reverse Transcriptase Inhibitor Efavirenz Reduces Neural Stem Cell Proliferation in Vitro and in Vivo.

Authors:  Jingji Jin; Bethany Grimmig; James Izzo; Lecia A M Brown; Charles Hudson; Adam J Smith; Jun Tan; Paula C Bickford; Brian Giunta
Journal:  Cell Transplant       Date:  2016-11       Impact factor: 4.064

Review 6.  HIV's double strike at the brain: neuronal toxicity and compromised neurogenesis.

Authors:  Marcus Kaul
Journal:  Front Biosci       Date:  2008-01-01

Review 7.  NeuroAIDS: characteristics and diagnosis of the neurological complications of AIDS.

Authors:  Alireza Minagar; Deborah Commins; J Steven Alexander; Romy Hoque; Francesco Chiappelli; Elyse J Singer; Behrooz Nikbin; Paul Shapshak
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

8.  Nuclear factor-kappa B family member RelB inhibits human immunodeficiency virus-1 Tat-induced tumor necrosis factor-alpha production.

Authors:  Michelle Kiebala; Oksana Polesskaya; Zhenqiang Yao; Seth W Perry; Sanjay B Maggirwar
Journal:  PLoS One       Date:  2010-07-29       Impact factor: 3.240

9.  Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains.

Authors:  Adarsh M Kumar; J B Fernandez; Elyse J Singer; Deborah Commins; Drenna Waldrop-Valverde; Raymond L Ownby; Mahendra Kumar
Journal:  J Neurovirol       Date:  2009-05       Impact factor: 2.643

10.  Β-funaltrexamine inhibits chemokine (CXCL10) expression in normal human astrocytes.

Authors:  Randall L Davis; Subhas Das; Daniel J Buck; Craig W Stevens
Journal:  Neurochem Int       Date:  2013-01-31       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.